Kailera Therapeutics, Inc. Common Stock (KLRA) - Net Assets
Based on the latest financial reports, Kailera Therapeutics, Inc. Common Stock (KLRA) has net assets worth $- USD as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Kailera Therapeutics, Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Kailera Therapeutics, Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Kailera Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore KLRA total asset value for the complete picture of this company's asset base.
Annual Net Assets for Kailera Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Kailera Therapeutics, Inc. Common Stock from 2024 to 2025. For live valuation and market cap data, see KLRA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-356.46 Million | -62.94% |
| 2024-12-31 | $-218.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kailera Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14895500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $12.21 Million | % |
| Total Equity | $-356.46 Million | 100.00% |
Kailera Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Kailera Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PHINIA Inc.
NYSE:PHIN
|
$2.73 Billion |
|
Hesai Group Sponsored ADR
NASDAQ:HSAI
|
$2.73 Billion |
|
Tianma Microelectronics Co Ltd
SHE:000050
|
$2.73 Billion |
|
Remitly Global Inc
NASDAQ:RELY
|
$2.73 Billion |
|
Alumis Inc
NASDAQ:ALMS
|
$2.73 Billion |
|
Sinocelltech Group Ltd
SHG:688520
|
$2.73 Billion |
|
Trinity Industries Inc
NYSE:TRN
|
$2.73 Billion |
|
Aroundtown SA
F:AT1
|
$2.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kailera Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -218,772,000 to -356,458,000, a change of -137,686,000.
- Net loss of 148,955,000 reduced equity.
- New share issuances of 498,874,000 increased equity.
- Other factors decreased equity by 487,605,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-148.96 Million | -41.79% |
| Share Issuances | $498.87 Million | +139.95% |
| Other Changes | $-487.61 Million | -136.79% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kailera Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Kailera Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-113.31 Million |
Industry Comparison
This section compares Kailera Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kailera Therapeutics, Inc. Common Stock (KLRA) | $- | 0.00% | N/A | $2.73 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more